Profil
Yaacov Koren has served as a director since January 2000.
He is Chief Executive Officer of Comverse Investments Ltd.
and has been Managing Director since July 1994.
Mr. Koren is Manager of the Comsor Venture Fund.
He was Chief Executive Officer of Batucha Securities and Investments Ltd.
Mr. Koren has 20 years of experience in the investment and financial industries.
He received his LLB.
from the Tel-Aviv University School of Law in 1982.
Anciens postes connus de Yaacov Koren
| Sociétés | Poste | Fin |
|---|---|---|
| Comverse Investments Ltd. | Corporate Officer/Principal | 26/01/2015 |
Ulticom, Inc.
 Ulticom, Inc. Packaged SoftwareTechnology Services Ulticom, Inc. provides telecommunications services. Its Signalware products are used by equipment manufacturers, application developers, and communication service providers to deploy infrastructure and services within the mobility, messaging, payment, and location markets. The firm also provides service essential signaling component and system solutions for wireless, wireline, and Internet communications. The company was founded in 1974 and is headquartered in Mount Laurel, NJ. | Directeur/Membre du Conseil | 27/12/2007 |
Collgard Biopharmaceuticals Ltd.
 Collgard Biopharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Collgard Biopharmaceuticals, the tissue therapeutics company, is developing drug treatments that target disease progression by directly influencing the tissue regeneration process. Central to Collgard's novel approach is its lead drug candidate, Tempostatin (Halofuginone hydrobromide). Tempostatin is a multi-indication, small-molecule drug candidate that has been identified by the company as influencing a 'master switch' in the body's tissue repair process. As a potent and selective regulator of stromal cell activation, cell migration and excessive collagen type I synthesis, Tempostatin makes it possible to harness and direct the tissue repair process for treating diseases acting at the tissue level. Collgard is developing therapeutic solutions for several clinical indications with significant unmet clinical needs. These solutions are based on highly specific control of the tissue repair process. Current programs target the following indications vascular restenosis, end-organ fibrosis, selected cancers and dermal fibroproliferative disorders. Tempostatin holds exceptional promise based on addressing a fundamental underlying pathological process that is not accessible to other current therapeutic approaches. In developing Tempostatin, Collgard seeks to offer novel therapeutic solutions as well as extend the effectiveness of existing therapies. Founded in 1996, Collgard Biopharmaceuticals is a privately held, clinical stage company, led by a global team of medical and drug development experts based in Atlanta and Tel Aviv. Scientific and clinical collaborators include The Mayo Clinic, the U.S. NCI, the EORTC, and Harvard Medical School. Collgard was founded by Medica Venture Partners. Additional investors include Mayo Medical Ventures, Denali Ventures, Yozma Group, and Comsor. | Directeur/Membre du Conseil | - |
Formation de Yaacov Koren
| Tel-Aviv University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Ulticom, Inc.
Ulticom, Inc. Packaged SoftwareTechnology Services Ulticom, Inc. provides telecommunications services. Its Signalware products are used by equipment manufacturers, application developers, and communication service providers to deploy infrastructure and services within the mobility, messaging, payment, and location markets. The firm also provides service essential signaling component and system solutions for wireless, wireline, and Internet communications. The company was founded in 1974 and is headquartered in Mount Laurel, NJ. | Technology Services |
| Comverse Investments Ltd. | Finance |
Collgard Biopharmaceuticals Ltd.
Collgard Biopharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Collgard Biopharmaceuticals, the tissue therapeutics company, is developing drug treatments that target disease progression by directly influencing the tissue regeneration process. Central to Collgard's novel approach is its lead drug candidate, Tempostatin (Halofuginone hydrobromide). Tempostatin is a multi-indication, small-molecule drug candidate that has been identified by the company as influencing a 'master switch' in the body's tissue repair process. As a potent and selective regulator of stromal cell activation, cell migration and excessive collagen type I synthesis, Tempostatin makes it possible to harness and direct the tissue repair process for treating diseases acting at the tissue level. Collgard is developing therapeutic solutions for several clinical indications with significant unmet clinical needs. These solutions are based on highly specific control of the tissue repair process. Current programs target the following indications vascular restenosis, end-organ fibrosis, selected cancers and dermal fibroproliferative disorders. Tempostatin holds exceptional promise based on addressing a fundamental underlying pathological process that is not accessible to other current therapeutic approaches. In developing Tempostatin, Collgard seeks to offer novel therapeutic solutions as well as extend the effectiveness of existing therapies. Founded in 1996, Collgard Biopharmaceuticals is a privately held, clinical stage company, led by a global team of medical and drug development experts based in Atlanta and Tel Aviv. Scientific and clinical collaborators include The Mayo Clinic, the U.S. NCI, the EORTC, and Harvard Medical School. Collgard was founded by Medica Venture Partners. Additional investors include Mayo Medical Ventures, Denali Ventures, Yozma Group, and Comsor. | Health Technology |